```html

Stomach Cancer (Gastric Carcinoma) – A Comprehensive Patient Guide

Overview

Stomach cancer, also called gastric carcinoma, is a malignant growth that originates in the lining of the stomach. It most often begins in the glandular cells that produce mucus and digestive juices. While the disease can occur at any age, the median age at diagnosis is 68 years.

Globally, stomach cancer is the fifth most common cancer and the third leading cause of cancer‑related death, accounting for ~1.1 million new cases and 770,000 deaths each year (World Health Organization, 2023). Incidence is highest in East Asia—particularly Japan, South Korea, and China—where dietary and infectious risk factors are more prevalent.

In the United States, the American Cancer Society estimates ≈ 27,600 new diagnoses and ≈ 11,000 deaths in 2024, representing about 1% of all cancers diagnosed in the country.

Symptoms

Early gastric cancer often produces vague or no symptoms, which is why it is frequently diagnosed at an advanced stage. When symptoms appear, they can be intermittent and may be mistakenly attributed to benign gastrointestinal problems.

Common signs & how they present

• Persistent indigestion or heartburn – A burning feeling that does not improve with over‑the‑counter antacids.
• Upper abdominal pain or discomfort – Dull, gnawing, or cramping pain that may worsen after meals.
• Feeling full after eating only a small amount (early satiety) – Because the tumor occupies space in the stomach.
• Unexplained weight loss – Loss of appetite and malabsorption can lead to rapid weight loss.
• Nausea or vomiting – Occasionally the tumor blocks the outlet of the stomach, causing vomiting of undigested food.
• Vomiting blood (hematemesis) – Bright red or coffee‑ground material indicates bleeding from the tumor.
• Black, tarry stools (melena) – Digested blood passing through the GI tract.
• Anemia – Fatigue, pallor, or shortness of breath from chronic blood loss.
• Swelling of the abdomen (ascites) – May develop in advanced disease when cancer spreads to the peritoneum.
• Difficulty swallowing (dysphagia) – Usually a sign that the tumor is near the gastro‑esophageal junction.

Causes and Risk Factors

Stomach cancer is multifactorial. No single cause has been identified, but several well‑studied risk factors increase the likelihood of developing gastric carcinoma.

Infectious agents

• Helicobacter pylori infection – Chronic infection damages the stomach lining and is responsible for up to 65% of non‑cardia gastric cancers (NIH, 2022).
• Epstein‑Barr virus (EBV) – Linked to a distinct molecular subtype of gastric cancer.

Dietary & lifestyle factors

• High intake of salted, smoked, or pickled foods (common in some Asian diets) – increases nitrosamine formation, a known carcinogen.
• Low consumption of fresh fruits and vegetables – reduces protective antioxidants.
• Heavy alcohol use – especially >2 drinks per day for women, >3 for men.
• Long‑term tobacco smoking – raises risk by ~30% (CDC, 2023).

Medical conditions

• Chronic atrophic gastritis or intestinal metaplasia.
• Gastric polyps (especially adenomatous polyps).
• Family history of gastric cancer or hereditary cancer syndromes (e.g., CDH1 mutation, Lynch syndrome).
• Previous stomach surgery (partial gastrectomy for ulcer disease).

Demographic factors

• Age > 50 years.
• Male sex – men are about twice as likely as women to develop the disease.
• Certain ethnicities – higher rates in East Asian, Hispanic, and Native American populations.

Diagnosis

Because early symptoms are subtle, a high index of suspicion is essential when risk factors are present. The diagnostic pathway typically involves a combination of imaging, endoscopic evaluation, and tissue sampling.

Initial evaluation

• Medical history & physical exam – Focus on weight loss, anemia, gastrointestinal bleeding, and risk factor assessment.
• Laboratory tests – Complete blood count (CBC) for anemia, liver function tests, and tumor markers (e.g., CEA, CA 19‑9) though not diagnostic.

Imaging studies

• Upper gastrointestinal (GI) series – Barium swallow can reveal filling defects.
• CT scan of the abdomen & pelvis – Stages disease, evaluates lymph nodes and distant spread.
• Endoscopic ultrasound (EUS) – Provides detailed depth of invasion and allows fine‑needle aspiration of suspicious nodes.
• Positron emission tomography (PET) – Helpful for detecting metastases in selected cases.

Endoscopic procedures

• Upper endoscopy (EGD) – Gold standard. Direct visualization and ability to obtain biopsies.
• Biopsy – At least 6–8 tissue samples from different areas of the lesion are recommended to reduce sampling error.

Pathology

Biopsy specimens are examined by a pathologist and classified according to the TNM staging system (Tumor size/extent, Node involvement, Metastasis). Molecular testing for HER2 amplification, microsatellite instability (MSI), and PD‑L1 expression guides targeted and immunotherapy options.

Treatment Options

Treatment is individualized based on tumor stage, location, molecular profile, and the patient’s overall health. Multidisciplinary care involving surgical oncology, medical oncology, radiation oncology, gastroenterology, nutrition, and supportive‑care teams yields the best outcomes.

Surgical treatment

• Gastrectomy – Removal of the tumor-bearing portion of the stomach. Types include:
  • Subtotal (distal) gastrectomy – most common for cancers in the lower two‑thirds.
  • Total gastrectomy – required for tumors near the gastro‑esophageal junction or diffuse disease.
• Lymph node dissection – D1 (limited) or D2 (extensive) nodal clearance improves staging accuracy and survival.
• Minimally invasive approaches – Laparoscopic or robotic gastrectomy provides similar oncologic outcomes with faster recovery in selected patients.

Radiation therapy

• Used as adjuvant (post‑surgery) to reduce local recurrence, especially after D1 dissection.
• Concurrent chemoradiation is standard for locally advanced disease not amenable to surgery.

Chemotherapy

Systemic therapy targets micrometastatic disease and can shrink tumors pre‑operatively (neoadjuvant) or eradicate residual cancer post‑operatively (adjuvant).

• Standard regimens (based on NCCN guidelines) include:
  • FLOT – 5‑fluorouracil, leucovorin, oxaliplatin, docetaxel (preferred peri‑operative regimen).
  • CAPOX – capecitabine + oxaliplatin.
  • S‑1 plus oxaliplatin (common in Asian protocols).
• Targeted therapy – Trastuzumab for HER2‑positive tumors (≈20% of cases).
• Immunotherapy – Pembrolizumab or nivolumab for tumors with high MSI or PD‑L1 CPS ≥10, per FDA approvals (2022).

Supportive & lifestyle measures

• Nutrition counseling – high‑protein, low‑sugar diet; small, frequent meals.
• Vitamin B12 supplementation after total gastrectomy (loss of intrinsic factor).
• Management of anemia – iron, folate, or transfusions as needed.
• Pain control – stepwise analgesic ladder; neuropathic agents for chemotherapy‑induced peripheral neuropathy.

Living with Stomach Cancer (Gastric Carcinoma)

Adapting to life after diagnosis involves practical steps that address physical, emotional, and social needs.

Nutrition and digestion

• Eat smaller, more frequent meals to prevent early satiety.
• Chew food thoroughly and choose soft, easy‑to‑digest textures (e.g., soups, smoothies).
• Avoid foods that irritate the stomach lining – very spicy, acidic, or high‑fat meals.
• Stay hydrated but sip fluids between meals rather than during meals.
• Consider a dietitian‑guided “**post‑gastrectomy diet**” that gradually re‑introduces fiber and protein.

Managing side effects

• Nausea – antiemetics (ondansetron, aprepitant) before chemotherapy.
• Diarrhea – loperamide; monitor electrolytes.
• Peripheral neuropathy – dose adjustments, gabapentin or duloxetine.
• Fatigue – regular light exercise, sleep hygiene, and energy‑conservation techniques.

Emotional and psychosocial health

• Join a support group (local hospital or online platforms such as Cancer Support Community).
• Seek counseling or psychotherapy to address anxiety, depression, or cancer‑related distress.
• Engage family and friends early; communicate needs and limits.

Follow‑up care

After curative treatment, most guidelines recommend:

• Clinic visits every 3–6 months for the first 2 years, then every 6–12 months.
• Routine labs (CBC, liver function), imaging (CT or endoscopy) based on stage and symptoms.
• Surveillance endoscopy for early‑stage disease, usually at 1 year and then as advised.

Prevention

While not all cases are preventable, modifying known risk factors can substantially lower the odds of developing gastric cancer.

• Eradicate Helicobacter pylori – Test‑and‑treat strategy for adults with dyspepsia or a family history; standard therapy: clarithromycin‑based triple regimen for 14 days.
• Adopt a diet rich in fruits, vegetables, and whole grains – Provides antioxidants and fiber.
• Limit salted, smoked, and processed meats – Aim for < 2 servings per week.
• Reduce alcohol consumption – No more than 1 drink per day for women, 2 for men.
• Quit smoking – Use nicotine replacement, prescription meds, or counseling programs.
• Maintain a healthy weight and engage in regular physical activity (≥150 min/week moderate aerobic exercise).

Complications

If stomach cancer progresses without appropriate treatment, several serious complications may arise:

• Obstruction – Tumor blocks the gastric outlet, causing vomiting, inability to eat, and dehydration.
• Bleeding – Ulceration of the tumor leads to chronic anemia or massive hemorrhage.
• Peritoneal carcinomatosis – Spread of cancer cells throughout the abdominal cavity causing ascites and bowel obstruction.
• Metastasis to liver, lungs, or distant lymph nodes – Leads to organ‑specific failure.
• Malnutrition and cachexia – Due to reduced intake and metabolic changes.
• Post‑surgical complications – Leak at the anastomosis site, infection, or nutrient deficiencies (e.g., B12, iron, calcium).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Cancer Institute, World Health Organization, Cleveland Clinic, American Cancer Society, NCCN Guidelines (2024), peer‑reviewed articles in The Lancet Oncology and Journal of Clinical Oncology.

```